Gene Bridges Announces Distribution Agreement with CAMBIO for Red/ET Recombination Kits
DRESDEN, Germany - Gene Bridges GmbH announced today, that CAMBIO Ltd., Cambridge, UK, has agreed to distribute Gene Bridges' Red/ET Recombination Kits in the United Kingdom & Ireland. "We are very pleased that a distribution organisation like CAMBIO, with such a strong market presence and reputation throughout United Kingdom has agreed to distribute our Red/ET Recombination Kits" says Gary Stevens, CEO of Gene Bridges. "Red/ET Recombination, also known as ET cloning or Lambda-mediated cloning, allows DNA constructs to be designed and created without size or site restrictions." The agreement includes the distribution of BAC Modification Kit, BAC Counter-Selection Kit, and BAC Subcloning Kit to non-commercial, research organisations. Commercial companies require a license from Gene Bridges.
CAMBIO sees the Red/ET kits as an ideal complement to their range of BAC libraries. Together they represent the key resources necessary for researchers to produce transgenic models with unprecedented ease. Now investigators can easily select and quickly obtain the BAC genomic sequence paired with the Red/ET kits for rapid production of transgenic constructs rather than labouring through the time-consuming process of subcloning and ligations. The Red/ET product line further extends CAMBIO's portfolio of products that expand investigators access to tools for systems biology."
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Modeling NAFLD with human pluripotent stem cell derived immature hepatocyte like cells
Agilent Thought Leader Award Presented to Renowned Drug Discovery Researcher Professor - Award to Chinese Scientist Supports the Use of Various Molecular Approaches to Cancer Research
Vitamins doing gymnastics: Scientists capture first full image of vitamin B12 in action - Work by University of Michigan and MIT team yields new understanding of crucial reaction in the body and in CO2-scrubbing bacteria
Positive Results in Proof-of-Concept Study with Sustained Release Treatment for Uveitis
Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan - Abbott will retain its branded generics pharmaceuticals business in emerging markets
Stanford researchers explore link between human birth defect syndrome, cancer metastasis
Asia-Pacific continues to drive global healthcare investment, innovation and growth ASEAN - A US$150 billion healthcare market by 2017, says Frost & Sullivan
Pharmacogenomics study finds rare gene variants critical for personalized drug treatment
Cambridge-based Startup Develops World’s Fastest Coronavirus-Killing Antiviral Protection
Evolva shareholders approve all Board proposals in AGM: Green light for Abunda acquisition
Aragen Bioscience, Inc. and CEVEC Sign License Agreement for Human CAP and CAP-T Technology
